Get in touchPrescribing informationAE reporting
Prescribing informationAE reporting
HomeNeuroblastoma and the unmet needIndicationHeritage
The QARZIBA® story
Neuroblastoma and the unmet needIndicationHeritage
How QARZIBA® works
How immunotherapy worksQARZIBA®'s mechanism of action
How immunotherapy worksQARZIBA®'s mechanism of action
QARZIBA® efficacy and safety profile
QARZIBA® efficacy dataQARZIBA® safety profile
QARZIBA® efficacy dataQARZIBA® safety profile
Resources
Infusion & administrationDosing calculator
Infusion & administrationDosing calculatorGet in touchPrescribing Information
Terms of usePrivacy policyCookie policyContact
Home
The QARZIBA® story
Indication

Indication¹

QARZIBA® is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures.1

In patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first-line therapy, QARZIBA® should be combined with interleukin-2 (IL-2).1

*Front-line high-risk neuroblastoma is defined as: Stage 4, 1 year; Stage 4(4s), <1 year with MYCN
amplification; Stage 2–3, 0–21 years with MYCN amplification.3

QARZIBA® is an important step forward for treating children with high-risk
neuroblastoma, in cases of newly-diagnosed, relapsed or refractory disease.

See below for how QARZIBA® fits into the treatment pathway:

High-risk neuroblastoma treatment pathway

*The use of IL-2 may be indicated in some scenarios. Please refer to your local product licence for guidance.

There is no clear pathway for relapsed/refractory patients, but patients
(with or without residual disease) may be treated with QARZIBA® once any
actively progressing disease has been stabilised.1,4

Other pages in this section

Neuroblastoma and the unmet need

Heritage

jamie-mum-path@2x

GL-DNB-2200034 | February 2023

Abbreviations

IL-2=interleukin-2.

References

  1. QARZIBA® (dinutuximab beta). Summary of product characteristics.
  2. EMA. Qarziba (previously dinutuximab beta EUSA and apeiron). Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/qarziba. Accessed February 2023.
  3. Ladenstein R et al. Oral Presentation. ASCO 2019.
  4. Ladenstein R et al. Cancers 2020; 12: 309.

This is a promotional website created by Recordati Rare Diseases and is intended for HCPs only.